References
1. Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer.2014;14(1):61-70.
2. Williams AM, Liu Q, Bhakta N, et al. Rethinking Success in Pediatric Oncology: Beyond 5-Year Survival. J Clin Oncol.2021;39(20):2227-2231.
3. Dixon SB, Liu Q, Chow EJ, et al. Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet. 2023;401(10386):1447-1457.
4. Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst. 1996;88(12):812-816.
5. Lund MJ, Eliason MT, Haight AE, Ward KC, Young JL, Pentz RD. Racial/ethnic diversity in children’s oncology clinical trials: ten years later. Cancer. 2009;115(16):3808-3816.
6. Faulk KE, Anderson-Mellies A, Cockburn M, Green AL. Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. PLoS One.2020;15(4):e0230824.
7. Flores-Toro JA, Jagu S, Armstrong GT, et al. The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. J Clin Oncol. 2023:JCO2202208.
8. Neel DV, Shulman DS, DuBois SG. Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer. 2019;112:49-56.
9. Zettler ME. The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs.Expert Rev Anticancer Ther. 2022;22(3):317-321.
10. Parsons DW, Janeway KA, Patton DR, et al. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children’s Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022;40(20):2224-2234.
11. Bona K, Li Y, Winestone LE, et al. Poverty and Targeted Immunotherapy: Survival in Children’s Oncology Group Clinical Trials for High-Risk Neuroblastoma. J Natl Cancer Inst. 2021;113(3):282-291.
12. Gupta S, Dai Y, Chen Z, et al. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children’s Oncology Group cohort trials. Lancet Haematol. 2023;10(2):e129-e141.
13. Puthenpura V, Ji L, Xu X, et al. Loss to follow-up of minorities, adolescents, and young adults on clinical trials: A report from the Children’s Oncology Group. Cancer. 2023;129(10):1547-1556.
14. Schwartz AL, Alsan M, Morris AA, Halpern SD. Why Diverse Clinical Trial Participation Matters. N Engl J Med.2023;388(14):1252-1254.